



## Key Results\*

People no longer requiring treatment for LF:

**280 million**

People no longer requiring treatment for trachoma:

**114 million**

People no longer requiring treatment for onchocerciasis:

**6 million**

Trainings that build the expertise and capacity of country partners reached: **6.5 million** individuals

## Quick Facts\*

- Launched in 2006
- Began with 5 countries, expanding to 32
- To date, the U.S. government has allocated **\$886 million** to the USAID NTD Program
- **2.6 billion** treatments delivered to date
- **\$22 billion** leveraged in donated drugs
- **1.3 billion** people treated

USAID is the world's premier international development agency and a catalytic actor driving development results. USAID's work advances U.S. national security and economic prosperity, demonstrates American generosity, and promotes a path to recipient self-reliance and resilience.

## Neglected Tropical Diseases

Neglected tropical diseases are intricately linked to poverty and inequality. They pose a crushing burden, particularly on the poorest, most marginalized and hard to reach populations. These diseases take a heavy human toll, causing chronic illness, blindness, and physical disfigurements. These diseases tighten their grip on people and families by exacerbating malnutrition, delaying cognitive development and lead to an appreciable loss of productivity.

The USAID Neglected Tropical Diseases Program targets the most prevalent neglected tropical diseases that have proven, cost-effective health interventions.



**Lymphatic Filariasis**  
(elephantiasis)



**Blinding Trachoma**



**Onchocerciasis**  
(river blindness)



**Schistosomiasis**  
(snail fever)



**Soil Transmitted Helminths**  
(hookworm, roundworm, whipworm)

## Our Approach

USAID invests the greatest portion of its funding in areas that have the greatest potential to achieve the World Health Organization 2020 NTD control and elimination goals.

### MAP the disease burden

**Mapping pinpoints the geographic distribution of diseases, showing exactly which communities are at risk.** Through geographic information systems, diagnostics, smartphones and other tools, USAID and partners collect data that serves as a blueprint to design effective programs. This strong base of data enables countries to benefit from the drug donation program, accurately estimate drug quantities, and channel resources to the communities in need.

### DELIVER treatments

**Large-scale treatment programs are the centerpiece of our work.** USAID supports planning, logistics and community resource mobilization activities, working hand in hand with countries to deliver treatments through schools and community-based centers. This integrated approach, called mass drug administration, reaches more people in need and treats communities for multiple diseases at the same time.

### MEASURE the impact

**Measuring progress is an essential component of our program.** USAID monitors program results and supports impact evaluations that show whether treatment programs are reducing prevalence levels to a point where it is no longer a public health threat and mass drug administration can be stopped.

*USAID also invests in complementary interventions that advance the WHO 2020 goals.*

### Provide care and treatment for disability

USAID and country partners are working to alleviate or correct the morbidity, disability and disfigurement associated with NTDs through surgical support and limb care.

### Conduct Operational Research

USAID works with other donors on operational research to document best practices, strengthen the evidence base for effective interventions and remove barriers to program implementation.

### Develop new tools and diagnostics

USAID supports the development of diagnostic tools and new drugs that could speed up progress in achieving the World Health Organization 2020 targets for NTDs.

\*Results from 2018

## Over 10 years of results

	FY 2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Value of <b>Drug Donations</b> by Year		\$404 million	\$507 million	\$577 million	\$686 million	\$949 million	\$1 billion	\$2.5 billion	\$2.1 billion	\$2.2 billion	\$4.6 billion	\$3.3 billion	\$3.2 billion
Number of <b>Treatments Delivered</b> by Year	Program Begins	36 million	58 million	130 million	160 million	208 million	244 million	233 million	239 million	299 million	390 million	318 million	268 million

## Our Partnerships

We collaborate closely with country governments, multilateral institutions, bilateral agencies, nonprofits, pharmaceutical companies and private philanthropy. Strategic partnerships provide opportunities to draw upon the knowledge, expertise and resources from a diverse range of stakeholders. Through a range of partnerships, our program is unlocking new possibilities to accelerate the WHO 2020 NTD goals and the Sustainable Development Agenda.


## Leverage private sector donations to maximize tax dollars

Our success is underpinned by a dynamic public-private partnership with the pharmaceutical industry, enabling USAID to carry out the largest integrated NTD program in the world, ensuring that treatments reach those in need. Leading pharmaceutical companies have made unprecedented pledges to tackle the most common NTDs by providing drugs free of charge.

- Eisai Co., Ltd.
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co. Inc.
- Merck KGaA
- Pfizer

To date:

Every \$1 invested by the US Government



**HIGH IMPACT**

**63¢** per person

**LOW COST**

Leverages **\$26** in donated medicines for mass treatment campaigns totalling **\$19 BILLION** in value

## Where We Work

### Country Successes

USAID supported countries that have eliminated at least one disease, officially verified by the WHO:

**Lymphatic Filariasis:** Cambodia (2016), Togo (2017), Vietnam (2018)

**Onchocerciasis:** Colombia (2013), Ecuador (2014), Mexico (2015), Guatemala (2016)

**Trachoma:** Cambodia (2017), Laos (2017), Nepal (2018), Ghana (2018)

